Drug Profile
Research programme: targeted antibody cancer therapy - Novartis
Alternative Names: CDH6-ADC; Novartis 1; Novartis 2; Novartis 3Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer ImmunoGen; Novartis
- Class Antibodies; Immunoconjugates
- Mechanism of Action Alkylating agents; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer